HRP20041071A2 - Methods of treating hepatitis - Google Patents

Methods of treating hepatitis

Info

Publication number
HRP20041071A2
HRP20041071A2 HR20041071A HRP20041071A HRP20041071A2 HR P20041071 A2 HRP20041071 A2 HR P20041071A2 HR 20041071 A HR20041071 A HR 20041071A HR P20041071 A HRP20041071 A HR P20041071A HR P20041071 A2 HRP20041071 A2 HR P20041071A2
Authority
HR
Croatia
Prior art keywords
methods
treating hepatitis
patient
hepatitis
treating
Prior art date
Application number
HR20041071A
Other languages
English (en)
Inventor
B. Otterbein Leo
Augustine
Zuckerbraun Brian
Original Assignee
Yale University University of Pittsburgh of the Commonwealth Syste
M Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University University of Pittsburgh of the Commonwealth Syste, M Of Higher Education filed Critical Yale University University of Pittsburgh of the Commonwealth Syste
Publication of HRP20041071A2 publication Critical patent/HRP20041071A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Saccharide Compounds (AREA)
HR20041071A 2002-05-17 2003-05-16 Methods of treating hepatitis HRP20041071A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38152702P 2002-05-17 2002-05-17
PCT/US2003/015263 WO2003096977A2 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis

Publications (1)

Publication Number Publication Date
HRP20041071A2 true HRP20041071A2 (en) 2005-06-30

Family

ID=29550139

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20041071A HRP20041071A2 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis

Country Status (16)

Country Link
US (4) US20040052866A1 (pl)
EP (1) EP1505990B1 (pl)
JP (1) JP4549847B2 (pl)
CN (1) CN1668314B (pl)
AT (1) ATE521357T1 (pl)
CA (1) CA2485465A1 (pl)
DK (1) DK1505990T3 (pl)
EA (1) EA200401525A1 (pl)
ES (1) ES2372273T3 (pl)
HR (1) HRP20041071A2 (pl)
MX (1) MXPA04011426A (pl)
NO (1) NO20045056L (pl)
PL (1) PL205066B1 (pl)
RS (1) RS99304A (pl)
UA (1) UA83465C2 (pl)
WO (1) WO2003096977A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
CA2451266A1 (en) * 2001-06-21 2003-01-03 Beth Israel Deaconess Medical Center Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
CA2475209A1 (en) * 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2005522521A (ja) 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
ES2546280T3 (es) * 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
US7981448B2 (en) 2002-04-15 2011-07-19 University Of Pittsburgh Methods of treating necrotizing enterocolitis
PL205066B1 (pl) 2002-05-17 2010-03-31 Univ Pittsburgh Zastosowanie tlenku węgla do wytwarzania kompozycji farmaceutycznej
EA200401622A1 (ru) * 2002-06-05 2005-06-30 Йейл Юниверсити Способы лечения ангиогенеза, роста опухолей и метастазов
MXPA04012863A (es) * 2002-06-21 2005-03-31 Univ Pittsburgh Uso farmaceutico de oxido nitrico, heme oxigenasa-1 y productos de degradacion de heme.
WO2004043341A2 (en) * 2002-11-07 2004-05-27 University Of Pittsburgh Of The Commonwealth System Of Higher Education Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
US20040218547A1 (en) 2003-04-30 2004-11-04 Rhodey William George Process modification to maximize benzene production
WO2007073225A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
JPWO2007073006A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
EP2348848A4 (en) * 2008-10-03 2012-03-07 Charlotte Mecklenburg Hospital METHOD FOR TREATING HEPATITIS C INFECTION WITH METALOPORPHYRINES
HUE052999T2 (hu) 2009-05-27 2021-06-28 Mallinckrodt Hospital Products Ip Ltd Eszköz beosztásos szelep és nyomás alatti tartályszerelvény összefogására gallérral és a dugattyú szerelvény által történõ lineáris mûködtetéshez az eszközzel történõ folyadék kommunikációban a gyógyszer-bejuttatás szabályozása érdekében
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
WO2011002584A1 (en) * 2009-07-02 2011-01-06 The University Of Iowa Research Foundation Treatment of hepatitis c virus infections
ES2656237T3 (es) 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
US9987302B2 (en) 2011-08-09 2018-06-05 Beth Israel Deaconess Medical Center, Inc. Methods of treating DNA damage
JP6457749B2 (ja) * 2013-12-27 2019-01-23 ハウスウェルネスフーズ株式会社 Ｖｃａｍ−１発現抑制剤
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
CN108057032B (zh) * 2018-01-30 2020-06-05 中国人民解放军第二军医大学第二附属医院 阿尔维林在制备预防或治疗门脉高压症的药物中的应用
EP3524290A1 (en) * 2018-02-09 2019-08-14 Julius-Maximilians-Universitaet Wuerzburg Method and system for monitoring carbon monoxide (co) administration to ex-vivo fluids

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
WO1994018954A1 (en) * 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
EP0804244A1 (en) 1993-03-26 1997-11-05 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
EP0835115B1 (en) * 1995-06-30 2004-05-06 ZymoGenetics, Inc. 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists
US5702325A (en) 1996-01-30 1997-12-30 Icon Health & Fitness, Inc. Cabinet treadmill with handle
JP3707699B2 (ja) * 1996-02-27 2005-10-19 ヘンク ダブリュー コスター 追加的ガス投与器を有する換気システム
EP0914103B1 (en) * 1996-04-05 2006-06-28 The General Hospital Corporation Treatment of a hemoglobinopathy
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
ES2210585T3 (es) 1996-08-27 2004-07-01 Messer Griesheim Gmbh Medicamento que contiene hidrogeno.
DE69737562T2 (de) * 1996-09-27 2007-12-27 The Trustees Of Columbia University In The City Of New York Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US5876604A (en) * 1996-10-24 1999-03-02 Compact Membrane Systems, Inc Method of gasifying or degasifying a liquid
ES2243052T3 (es) 1998-03-16 2005-11-16 Celgene Corporation Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2812197B1 (fr) 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
IL158182A0 (en) * 2001-03-30 2004-03-28 Sangstat Medical Corp Carbon monoxide generating compounds for treatment of vacular, inflammatory and immune disorders
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1395241B9 (en) * 2001-05-25 2005-06-15 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
CA2451266A1 (en) * 2001-06-21 2003-01-03 Beth Israel Deaconess Medical Center Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US7174178B2 (en) 2001-07-19 2007-02-06 Intel Corporation Deriving a more accurate estimate from prediction data in closed loop transmit diversity modes
CA2475209A1 (en) 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US7364757B2 (en) * 2002-02-13 2008-04-29 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating vascular disease
ES2546280T3 (es) 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
JP2005522521A (ja) * 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
US7981448B2 (en) 2002-04-15 2011-07-19 University Of Pittsburgh Methods of treating necrotizing enterocolitis
MXPA04011113A (es) * 2002-05-09 2005-02-14 Univ Johns Hopkins Monoxido de carbono en la forma de biomarcador y agente terapeutico.
PL205066B1 (pl) 2002-05-17 2010-03-31 Univ Pittsburgh Zastosowanie tlenku węgla do wytwarzania kompozycji farmaceutycznej
EA200401622A1 (ru) * 2002-06-05 2005-06-30 Йейл Юниверсити Способы лечения ангиогенеза, роста опухолей и метастазов
MXPA04012863A (es) 2002-06-21 2005-03-31 Univ Pittsburgh Uso farmaceutico de oxido nitrico, heme oxigenasa-1 y productos de degradacion de heme.
DE10230165A1 (de) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
WO2004043341A2 (en) 2002-11-07 2004-05-27 University Of Pittsburgh Of The Commonwealth System Of Higher Education Treatment for hemorrhagic shock
WO2005077005A2 (en) 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas

Also Published As

Publication number Publication date
RS99304A (sr) 2007-04-10
ATE521357T1 (de) 2011-09-15
US20140141103A1 (en) 2014-05-22
MXPA04011426A (es) 2005-10-19
CN1668314B (zh) 2011-01-12
EA200401525A1 (ru) 2006-06-30
NO20045056L (no) 2005-02-16
US20040052866A1 (en) 2004-03-18
WO2003096977A2 (en) 2003-11-27
CA2485465A1 (en) 2003-11-27
US20120276220A1 (en) 2012-11-01
US9522163B2 (en) 2016-12-20
UA83465C2 (uk) 2008-07-25
EP1505990A4 (en) 2008-02-20
PL374177A1 (pl) 2005-10-03
CN1668314A (zh) 2005-09-14
AU2003234585A1 (en) 2003-12-02
ES2372273T3 (es) 2012-01-17
JP4549847B2 (ja) 2010-09-22
PL205066B1 (pl) 2010-03-31
JP2005533021A (ja) 2005-11-04
DK1505990T3 (da) 2011-11-21
EP1505990A2 (en) 2005-02-16
EP1505990B1 (en) 2011-08-24
US20130202720A1 (en) 2013-08-08
WO2003096977A3 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
HRP20041071A2 (en) Methods of treating hepatitis
UA85041C2 (ru) Способ лечения кишечной непроходимости
UA86570C2 (ru) Способ лечения некротизирующего энтероколита
PL373229A1 (pl) Sposób podawania i urządzenie do podawania tlenkuwęgla (CO)
EP1670450A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING LEVODOPA AND CARBIDOPA
WO2004043341A3 (en) Treatment for hemorrhagic shock
TW200738270A (en) Method of treating depression using a TNFα antibody
MY142777A (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
IL173002A (en) Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritis
MXPA05009786A (es) Composicion para administracion de hierro para el tratamiento del sindrome de piernas inquietas.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
TW200509984A (en) Injectable dosage form of flupirtine
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
MXPA05005915A (es) Soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas.
PL375354A1 (pl) Zastosowanie treosulfanu i jego pochodnych do leczenia stwardnienia rozsianego
DE60335535D1 (de) Zusammensetzung und verfahren zur abtötung von tumoren
UA29106A (uk) Спосіб лікування вібраційної хвороби
UA36555A (uk) Спосіб відновлення опорної частини зруйнованої кукси зуба

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100507

Year of fee payment: 8

OBST Application withdrawn